Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?

Journal of Clinical Oncology

Volumn 27, Issue 15, 2009, Pages 2567-2569

  Bamias, Aristotle ^a   Lainakis, George ^a   Manios, Efstathios ^a   Koroboki, Eleni ^a   Karadimou, Alexandra ^a   Zakopoulos, Nikos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; NEBIVOLOL; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; BLOOD PRESSURE; CARDIOTOXICITY; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY CARCINOMA; LETTER; MEASUREMENT; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; KIDNEY TUMOR; NOTE;

CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; HEART; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 66349094554     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6028     Document Type: Letter

References (5)

1. Schmidinger M, Zielinski CC, Vogl UM, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212, 2008
2. Mancia G, De Backer G, Dominiczak A, et al: Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007
3. Lainakis G, Bamias A, Manios E, et al: 24-hour arterial blood pressure monitoring in patients with renal cell carcinoma treated with sunitinib results in control of hypertension without dose reduction in the majority of patients. Ann Oncol 18:195, 2008 (suppl; abstr 603P)
4. Bhojani N, Jeldres C, Patard JJ, et al: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917-930, 2008
5. Azizi M, Chedid A, Oudard S: Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358:95-96, 2008